8-KEarnings & ResultsOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jul 23, 2009)

Filed July 23, 2009For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K report on July 23, 2009, announcing two significant events. Firstly, the company released its second-quarter 2009 financial results via a press release, with accompanying supplemental investor presentations and information available on its website. This provides investors with an update on the company's operational and financial performance during the period. Secondly, and of potentially greater strategic importance, BMY announced its definitive agreement to acquire Medarex, Inc. for $16.00 per share in cash. This acquisition signals a key move by Bristol-Myers Squibb to bolster its biotechnology pipeline and future growth prospects. Investors will want to closely examine the details of the Q2 results and understand the strategic rationale and financial implications of the Medarex acquisition.

Key Highlights

  • 1Bristol-Myers Squibb announced its second-quarter 2009 financial results on July 23, 2009.
  • 2Detailed financial results, investor presentations, and supplemental information are publicly available.
  • 3BMY entered into a definitive merger agreement to acquire Medarex, Inc.
  • 4The acquisition of Medarex is valued at $16.00 per share in cash.
  • 5The acquisition is a significant strategic move to enhance BMY's pipeline and future growth.
  • 6The company also filed press releases detailing both the Q2 results and the Medarex acquisition.

Frequently Asked Questions

The filing announces the release of Bristol-Myers Squibb's second-quarter 2009 financial results. Investors can access these results, along with supplemental presentations and information, through the press release furnished with this 8-K and on the company's website.

The acquisition of Medarex, Inc. for $16.00 per share in cash is a major strategic development. It indicates Bristol-Myers Squibb's intent to expand its capabilities and pipeline, likely in the area of biotechnology, which could drive future revenue and innovation.

The definitive merger agreement for the acquisition of Medarex, Inc. was announced on July 22, 2009, with the press release filed as part of this 8-K.

More detailed information can be found in the press releases (Exhibit 99.1 and 99.4) furnished with this 8-K, as well as in the supplemental investor presentation (Exhibit 99.2) and supplemental information (Exhibit 99.3) posted on Bristol-Myers Squibb's website (www.bms.com).